Next Article in Journal
Managing the Acute Painful Episode in Sickle Cell Disease
Previous Article in Journal
Pain and Bone Disease: A Patient’s View
 
 
Thalassemia Reports is published by MDPI from Volume 12 Issue 1 (2022). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with PAGEPress.
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

New Antiviral Agents and New Treatments on the Horizon for the Management of Viral Hepatitis

Yeditepe University Hospital, Infectious Diseases Department, Istanbul, Turkey
Thalass. Rep. 2011, 1(s2), e27; https://doi.org/10.4081/thal.2011.s2.e27
Submission received: 1 December 2011 / Revised: 15 December 2011 / Accepted: 27 December 2011 / Published: 30 December 2011

Abstract

Transfusion dependant patients are at risk of acquiring transfusiontransmitted viral infections including Hepatitis B virus (HBV) and Hepatitis C (HCV). These infections can lead to cirrhosis and hepatic cancer. Standard treatment, although with improved therapeutic results still exhibits resistance and relapses. New antiviral agents have been developed to further improve results and reduce adverse events. For hepatitis B, along with pegylated interferon α-2α, other drugs that have been approved include lamivudine, adefovir, entecavir, telbivudine and tenofovir, while emtricitabine and clevudine are awaiting FDA approval. Possible combination drug therapy may improve efficacy without engendering resistance. For hepatitis C, standard therapy has been the combination of Peg-IFN/Ribavarin. Genotype 1 of the virus, which is widespread in the USA and Europe, can be resistant to treatment especially with high viral load. Directly acting antiviral agents (DAAs), are being developed. These are: (i) HCV NS3 protease inhibitors, such as telaprevir and boceprevir, which are currently approved by the FDA. Several other compounds are in phase I-II development; (ii) NS5B polymerase inhibitors, which target HCV replication. These include mericitabine (a nucleoside analogue inhibitor) currently in phase III trials, and nonnucleiside inhibitors; (iii) New intreferons such as pgylated interferonl λ, which are also on trial. Triple therapy using pegylated IFNa/ Ribavarin along with telaprevir or boceprevir are also under trial.
Keywords: viral; hepatitis; antiviral agents viral; hepatitis; antiviral agents

Share and Cite

MDPI and ACS Style

Sönmezoğlu, M. New Antiviral Agents and New Treatments on the Horizon for the Management of Viral Hepatitis. Thalass. Rep. 2011, 1, e27. https://doi.org/10.4081/thal.2011.s2.e27

AMA Style

Sönmezoğlu M. New Antiviral Agents and New Treatments on the Horizon for the Management of Viral Hepatitis. Thalassemia Reports. 2011; 1(s2):e27. https://doi.org/10.4081/thal.2011.s2.e27

Chicago/Turabian Style

Sönmezoğlu, M. 2011. "New Antiviral Agents and New Treatments on the Horizon for the Management of Viral Hepatitis" Thalassemia Reports 1, no. s2: e27. https://doi.org/10.4081/thal.2011.s2.e27

Article Metrics

Back to TopTop